Loading
A phase 1/2 trial of Pembrolizumab, Atezolizumab, Bevacizumab in hepatocellular carcinoma, run by Tvardi Therapeutics, Incorporated, now recruiting.
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma is a phase 1/2 interventional study registered as NCT05440708 by Tvardi Therapeutics, Incorporated, with 193 participants planned, started 2023-03-23 and due to reach its primary completion in 2027-02-01. Interventions recorded: TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.